In many western countries, an MRI before biopsy is a standard part of diagnosing suspected prostate cancer. In the United States, however, that approach is still not routine. The latest data cited by STAT show that pre-biopsy MRI was used in only about a third of U.S. prostate cancer cases in 2022.
The gap stands out because prostate cancer is the most frequently diagnosed cancer among American men, with more than 333,000 new cases each year. Even though it is common, it is generally considered less deadly than many other major cancers, making accurate diagnosis especially important when deciding who needs further testing and treatment.
A pre-biopsy MRI can help identify suspicious areas before tissue is sampled, which may improve how a biopsy is planned. That is one reason the scan has become standard practice in much of the western world. The U.S. numbers suggest many patients are still moving through diagnosis without that extra imaging step.
The difference points to a broader divide between accepted international practice and what many American men actually receive. As prostate cancer remains so widespread, the relatively low use of pre-biopsy MRI in the U.S. is drawing attention as a significant issue in cancer diagnosis.
